Indications and uses
helps prevent sunburn
NARS FOUNDATION
- Manufacturer
- NARS Cosmetics | SHISEIDO AMERICA INC. | Davlyn Industries Inc
- Effective date
- 2012-10-25
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 01:44:12
Label at a glance#
ProductNARS FOUNDATION Barcelona
Active ingredientOCTINOXATE, TITANIUM DIOXIDE
Label structure21 sections
Dosage and administration
apply liberally 15 minutes before sun exposure use a water resistant sunscreen if swimming or sweating reapply at least every 2 hours children under 6 months: Ask a doctor
Storage and handling
protect this product in this container from excessive heat and direct sun
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Drug Facts
OTC - ACTIVE INGREDIENT SECTION
OTC - PURPOSE SECTION
| Active ingredients | Purpose |
|---|---|
| OCTINOXATE 4.9% | Sunscreen |
| TITANIUM DIOXIDE 6.6% | Sunscreen |
Uses
- helps prevent sunburn
Warnings
Skin Cancer/Skin Aging Alert
Spending time in the sun increases your risk of skin cancer and early skin aging. This product has been shown only to prevent sunburn, not skin cancer or early skin aging.
OTC - DO NOT USE SECTION
For external use only
Do not use on damaged or broken skin
OTC - WHEN USING SECTION
When using this product keep out of eyes. Rinse with water to remove.
OTC - STOP USE SECTION
Stop use and ask a doctor if rash occurs
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children. If product is swallowed, get medical help or contact a Poison Control Center right away.
Directions
- apply liberally 15 minutes before sun exposure
- use a water resistant sunscreen if swimming or sweating
- reapply at least every 2 hours
- children under 6 months: Ask a doctor
Inactive Ingredients
NYLON-12 , CALCIUM STEARATE , SILICA , DIMETHICONE , JOJOBA ALCOHOL , ISOPROPYL JOJOBATE , JOJOBA ESTERS , HYDROGENATED LECITHIN , TRIMETHYLSILOXYSILICATE , LAUROYL LYSINE , METHICONE , SORBITAN SESQUIOLEATE , METHYLPARABEN , PROPYLPARABEN , BHT , TOCOPHEROL , [(MAY CONTAIN): MICA , TITANIUM DIOXIDE , IRON OXIDES , IRON OXIDES , IRON OXIDES] ,
Other information
protect this product in this container from excessive heat and direct sun
Questions or comments?
Call toll free 1-888-788-NARS
PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - BARCELONA
NARS
POWDER FOUNDATION BROAD SPECTRUM
SPF 12 SUNSCREEN
NET WT. 0.42 Oz. 12 g
PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - BENARES
NARS
POWDER FOUNDATION BROAD SPECTRUM
SPF 12 SUNSCREEN
NET WT. 0.42 Oz. 12 g
PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - CÁDIZ
NARS
POWDER FOUNDATION BROAD SPECTRUM
SPF 12 SUNSCREEN
NET WT. 0.42 Oz. 12 g
PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - DEAUVILLE
NARS
POWDER FOUNDATION BROAD SPECTRUM
SPF 12 SUNSCREEN
NET WT. 0.42 Oz. 12 g
PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - FIJI
NARS
POWDER FOUNDATION BROAD SPECTRUM
SPF 12 SUNSCREEN
NET WT. 0.42 Oz. 12 g
PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - MONT BLANC
NARS
POWDER FOUNDATION BROAD SPECTRUM
SPF 12 SUNSCREEN
NET WT. 0.42 Oz. 12 g
PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - NEW ORLEANS
NARS
POWDER FOUNDATION BROAD SPECTRUM
SPF 12 SUNSCREEN
NET WT. 0.42 Oz. 12 g
PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - PUNJAB
NARS
POWDER FOUNDATION BROAD SPECTRUM
SPF 12 SUNSCREEN
NET WT. 0.42 Oz. 12 g
PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - SANTA FE
NARS
POWDER FOUNDATION BROAD SPECTRUM
SPF 12 SUNSCREEN
NET WT. 0.42 Oz. 12 g
PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - SIBERIA
NARS
POWDER FOUNDATION BROAD SPECTRUM
SPF 12 SUNSCREEN
NET WT. 0.42 Oz. 12 g
PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - STROMBOLI
NARS
POWDER FOUNDATION BROAD SPECTRUM
SPF 12 SUNSCREEN
NET WT. 0.42 Oz. 12 g
PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - SYRACUSE
NARS
POWDER FOUNDATION BROAD SPECTRUM
SPF 12 SUNSCREEN
NET WT. 0.42 Oz. 12 g
PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - TAHOE
NARS
POWDER FOUNDATION BROAD SPECTRUM
SPF 12 SUNSCREEN
NET WT. 0.42 Oz. 12 g
FDA-Initiated Inactive NDC Indexing#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| OCTINOXATE | ACTIVE INGREDIENT | 4Y5P7MUD51 | 1 | |
| TITANIUM DIOXIDE | ACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| OCTINOXATE | ACTIVE MOIETY | 4Y5P7MUD51 | 1 | |
| TITANIUM DIOXIDE | ACTIVE MOIETY | 15FIX9V2JP | 1 | |
| .ALPHA.-TOCOPHEROL | INACTIVE INGREDIENT | H4N855PNZ1 | 1 | |
| BUTYLATED HYDROXYTOLUENE | INACTIVE INGREDIENT | 1P9D0Z171K | 1 | |
| CALCIUM STEARATE | INACTIVE INGREDIENT | 776XM7047L | 1 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 1 | |
| FERRIC OXIDE RED | INACTIVE INGREDIENT | 1K09F3G675 | 1 | |
| FERRIC OXIDE YELLOW | INACTIVE INGREDIENT | EX438O2MRT | 1 | |
| FERROSOFERRIC OXIDE | INACTIVE INGREDIENT | XM0M87F357 | 1 | |
| LAUROYL LYSINE | INACTIVE INGREDIENT | 113171Q70B | 1 | |
| METHICONE (20 CST) | INACTIVE INGREDIENT | 6777U11MKT | 1 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 1 | |
| MICA | INACTIVE INGREDIENT | V8A1AW0880 | 1 | |
| NYLON-12 | INACTIVE INGREDIENT | 446U8J075B | 1 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 1 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| SORBITAN SESQUIOLEATE | INACTIVE INGREDIENT | 0W8RRI5W5A | 1 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| TRIMETHYLSILOXYSILICATE (M/Q 0.6-0.8) | INACTIVE INGREDIENT | 5041RX63GN | 1 |
Products#
Every source-derived product name is available through these pages.
- NARS FOUNDATION Barcelona
- OCTINOXATE and TITANIUM DIOXIDE
- OCTINOXATE
- TITANIUM DIOXIDE
- NYLON-12
- CALCIUM STEARATE
- SILICON DIOXIDE
- DIMETHICONE
- TRIMETHYLSILOXYSILICATE (M/Q 0.6-0.8)
- LAUROYL LYSINE
- METHICONE (20 CST)
- SORBITAN SESQUIOLEATE
- METHYLPARABEN
- PROPYLPARABEN
- BUTYLATED HYDROXYTOLUENE
- .ALPHA.-TOCOPHEROL
- MICA
- FERRIC OXIDE RED
- FERRIC OXIDE YELLOW
- FERROSOFERRIC OXIDE
- NARS FOUNDATION Benares
- NARS FOUNDATION Cadiz
- NARS FOUNDATION Deauville
- NARS FOUNDATION Fiji
- NARS FOUNDATION Mont Blanc
- NARS FOUNDATION New Orleans
- NARS FOUNDATION Punjab
- NARS FOUNDATION Santa Fe
- NARS FOUNDATION Siberia
- NARS FOUNDATION Stromboli
- NARS FOUNDATION Syracuse
- NARS FOUNDATION Tahoe
NDC Codes#
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET, COATED / ORAL | 0.8 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | PASTE, DENTIFRICE / DENTAL | 0.4 %w/w | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, DELAYED RELEASE / ORAL | 7 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, CHEWABLE / ORAL | 14 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | JELLY / TOPICAL | 180 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | PELLET / ORAL | 34 mg | ||
| .ALPHA.-TOCOPHEROL | .ALPHA.-TOCOPHEROL | H4N855PNZ1 | FILM, SOLUBLE / BUCCAL | 0.07 mg | ||
| .ALPHA.-TOCOPHEROL | .ALPHA.-TOCOPHEROL | H4N855PNZ1 | TABLET, FILM COATED / ORAL | 246 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION, CONCENTRATE / ORAL | 1 mg/1ml | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | TABLET / ORAL | 3 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | GUM, CHEWING / BUCCAL | 5 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SPRAY / TOPICAL | 0.2 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | TABLET, CHEWABLE / ORAL | 0.14 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 0.8 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / ORAL | 300 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 42 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | POWDER / ORAL | NA | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | DROPS / OPHTHALMIC | 0.01 %w/w | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SOLUTION, CONCENTRATE / ORAL | 0.1 mg/1ml | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CAPSULE, EXTENDED RELEASE / ORAL | 0.22 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | ENEMA / RECTAL | 0.18 %w/v | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | PASTE / DENTAL | 34 %w/w | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | OINTMENT / TOPICAL | 57 mg | ||
| .ALPHA.-TOCOPHEROL | .ALPHA.-TOCOPHEROL | H4N855PNZ1 | SOLUTION / ORAL | 1.05 mg/1ml | ||
| CALCIUM STEARATE | CALCIUM STEARATE | 776XM7047L | TABLET / ORAL | 280 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | GRANULE, FOR SUSPENSION / ORAL | 80 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CAPSULE / ORAL | 7 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SUPPOSITORY / RECTAL | 1 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SYSTEM / TRANSDERMAL | 35 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | LOTION / TOPICAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | DROPS / NASAL | 26 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | POWDER, FOR SUSPENSION / ORAL | 8 mg | ||
| .ALPHA.-TOCOPHEROL | .ALPHA.-TOCOPHEROL | H4N855PNZ1 | SYSTEM / TOPICAL | 0.1 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | DROPS / ORAL | NA | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SPRAY / TOPICAL | 0.8 %w/w | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED PELLETS / ORAL | 69 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | GEL / TOPICAL | 4 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INFILTRATION | 80 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / ORAL | 24 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | FILM, SOLUBLE / BUCCAL | 3 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRAMUSCULAR | 6 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / NASAL | 20 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, COATED / ORAL | 176 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, EXTENDED RELEASE / ORAL | 15 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | EMULSION / TOPICAL | 0.06 %w/w | ||
| .ALPHA.-TOCOPHEROL | .ALPHA.-TOCOPHEROL | H4N855PNZ1 | TABLET, CHEWABLE / ORAL | 0.1 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | CAPSULE / ORAL | 14 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SOLUTION / INTRAVENOUS | 5 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER / RESPIRATORY (INHALATION) | 2 mg | ||
| CALCIUM STEARATE | CALCIUM STEARATE | 776XM7047L | POWDER / ORAL | 600 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 0.15 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 24 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | LOTION / TOPICAL | 140 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CONCENTRATE / ORAL | 2.5 mg/5ml | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE / ORAL | 72 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / OPHTHALMIC | 0.02 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION/ DROPS / OPHTHALMIC | 0.01 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / INTRAVENOUS | 45 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | GRANULE, FOR SUSPENSION / ORAL | 143 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / PERINEURAL | 80 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 84a12536-f9fe-4088-a1d0-28aa69b795c2 | 5034b928-2bd9-4350-976b-14811b68886d | 2023-09-11 | Warnings | 5034b928-2bd9-4350-976b-14811b68886d |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.